Prognostic Factors and Characteristics of Pancreatic Neuroendocrine Tumors: Single Center Experience
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Pancreatic neuroendocrine tumors (PNET) are a rare subgroup of tumors. For PNETs, the predictive factors for survival and prognosis are not well known. The purpose of our study was to evaluate the predictive factors for survival and disease progression in PNETs. Materials and Methods: We retrospectively analyzed 37 patients who were diagnosed with PNET at Severance Hospital between November 2005 and March 2010. Prognostic factors for survival and disease progression were evaluated using the Kaplan-Meier method. Results: The mean age of the patients was 50.0±15.0 years. Eight cases (21.6%) were described as functioning tumors and 29 cases (78.4%) as non-functioning tumors. In univariate analysis of clinical factors, patients with liver metastasis (p=0.002), without resection of primary tumors (p=0.002), or American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC) stage III/IV (p=0.002) were more likely to demonstrate shorter overall survival (OS). Patients with bile duct or pancreatic duct invasion (p=0.031), sized-lesions larger than 20 mm (p=0.036), liver metastasis (p=0.020), distant metastasis (p=0.005), lymph node metastasis (p=0.009) or without resection of primary tumors (p=0.020) were more likely to demonstrate shorter progression-free survival (PFS). In multivariate analysis of clinical factors, bile duct or pancreatic duct invasion [p=0.010, hazard ratio (HR)=95.046] and tumor location (non-head of pancreas) (p=0.036, HR=7.381) were confirmed as independent factors for predicting shorter PFS. Conclusion: Patients with liver metastasis or without resection of primary tumors were more likely to demonstrate shorter OS. Patients with bile duct or pancreatic duct invasion or tumors located at body or tail of pancreas were more likely to demonstrate shorter PFS.
Abstract
Purpose: Pancreatic neuroendocrine tumors (PNET) are a rare subgroup of tumors. For PNETs, the predictive factors for survival and prognosis are not well known. The purpose of our study was to evaluate the predictive factors for survival and disease progression in PNETs. Materials and Methods: We retrospectively analyzed 37 patients who were diagnosed with PNET at Severance Hospital between November 2005 and March 2010. Prognostic factors for survival and disease progression were evaluated using the Kaplan-Meier method. Results: The mean age of the patients was 50.0±15.0 years. Eight cases (21.6%) were described as functioning tumors and 29 cases (78.4%) as non-functioning tumors. In univariate analysis of clinical factors, patients with liver metastasis (p=0.002), without resection of primary tumors (p=0.002), or American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC) stage III/IV (p=0.002) were more likely to demonstrate shorter overall survival (OS). Patients with bile duct or pancreatic duct invasion (p=0.031), sized-lesions larger than 20 mm (p=0.036), liver metastasis (p=0.020), distant metastasis (p=0.005), lymph node metastasis (p=0.009) or without resection of primary tumors (p=0.020) were more likely to demonstrate shorter progression-free survival (PFS). In multivariate analysis of clinical factors, bile duct or pancreatic duct invasion [p=0.010, hazard ratio (HR)=95.046] and tumor location (non-head of pancreas) (p=0.036, HR=7.381) were confirmed as independent factors for predicting shorter PFS. Conclusion: Patients with liver metastasis or without resection of primary tumors were more likely to demonstrate shorter OS. Patients with bile duct or pancreatic duct invasion or tumors located at body or tail of pancreas were more likely to demonstrate shorter PFS.
참고문헌 (22)
- Oberg K, "Endocrine tumours of the pancreas", Best Pract Res Clin Gastroenterol, 19, pp.753~781 (2005)
- Eriksson B, "Neuroendocrine tumours of the pancreas", Br J Surg, 87, pp.129~131 (2000)
- Ong SL, "A fuller understanding of pancreatic neuroendocrine tumours combined with aggressive management improves outcome", Pancreatology, 9, pp.583~600 (2009)
- Ehehalt F, "Neuroendocrine tumors of the pancreas", Oncologist, 14, pp.456~467 (2009)
- Norton JA, "Aggressive surgery for metastatic liver neuroendocrine tumors", Surgery, 134, pp.1057~1063 (2003)
- Chen H, "Isolated liver metastases from neuroendocrine tumors: does resection prolong survival?", J Am Coll Surg, 187, pp.88~92 (1998)
- 한정혜, "췌장의 신경내분비 종양 122예의 임상양상 및 악성 예측인자", 대한소화기학회지, 53(2), pp.98~105 (2009), 대한소화기학회
- 백우현, "췌장내분비종양의 임상 양상과 생존과 연관된 예후 인자", 대한소화기학회지, 52(3), pp.171~178 (2008), 대한소화기학회
- 강태욱, "췌장의 신경내분비 종양 43예의 임상 고찰: 단일센터 경험", 대한소화기학회지, 48(2), pp.112~118 (2006), 대한소화기학회
- Panzuto F, "Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization", Endocr Relat Cancer, 12, pp.1083~1092 (2005)
- Metz DC, "Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors", Gastroenterology, 135, pp.1469~1492 (2008)
- Nobels FR, "Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones", J Clin Endocrinol Metab, 82, pp.2622~2628 (1997)
- Zimmer T, "Endoscopic ultrasonography and somatostatin receptor scintigraphy in the preoperative localisation of insulinomas and gastrinomas", Gut, 39, pp.562~568 (1996)
- Pape UF, "Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors", Cancer, 113, pp.256~265 (2008)
- Rindi G, "TNM staging of foregut (neuro) endocrine tumors: a consensus proposal including a grading system", Virchows Arch, 449, pp.395~401 (2006)
- Edge SB, "The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM", Ann Surg Oncol, 17, pp.1471~1474 (2010)
- Hill JS, "Pancreatic neuroendocrine tumors: the impact of surgical resection on survival", Cancer, 115, pp.741~751 (2009)
- Hodul PJ, "Aggressive surgical resection in the management of pancreatic neuroendocrine tumors: when is it indicated?", Cancer Control, 15, pp.314~321 (2008)
- Liu H, "Diagnosis and surgical treatment of pancreatic endocrine tumors in 36 patients: a single-center report", Chin Med J, 120, pp.1487~1490 (2007)
- Kaemmerer D, "Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor", World J Gastroenterol, 15, pp.5867~5870 (2009)
- Strosberg J, "Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors", World J Gastroenterol, 16, pp.2963~2970 (2010)
- Massironi S, "Neuroendocrine tumors of the gastro-entero-pancreatic system", World J Gastroenterol, 14, pp.5377~5384 (2008)